跳至主要内容
临床试验/NL-OMON54025
NL-OMON54025招募中不适用

Cancer-associated venous thromboembolism: unfolding the role of the intrinsic coagulation pathway - CELESTA study

Academisch Medisch Centrum0 个研究点目标入组 100 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • 1. Patients with active cancer and acute venous thromboembolism (VTE) in whom
  • anticoagulant therapy is anticipated
  • 2. Patients with active cancer and no suspicion or history of VTE
  • 3. Patients with acute venous thromboembolism in whom anticoagulant therapy is
  • anticipated, with no history of cancer or cancer treatment in the past 5 years
  • and no suspicion of cancer at study entry.
  • 4. Healthy volunteers
  • No history of cancer or cancer-related therapy in the past 5 years.
  • No history of VTE
  • No suspicion of cancer or VTE at study entry
  • No hospital admission in the past 6 months

排除标准

  • Arterial thrombosis (ischemic stroke, myocardial infarction, peripheral
  • arterial thrombosis) in the past six months
  • Ongoing anticoagulant or antiplatelet therapy
  • Mechanical heart valves
  • Central venous catheters within 4 weeks prior to inclusion, or anticipated
  • One or more of the following risk factors for VTE:
  • - Known hereditary or acquired thrombophilia
  • - Viral or bacterial infection at time of inclusion
  • - Surgery, trauma or fracture of the leg within the previous 4 weeks
  • - Current known pregnancy
  • - Current estrogen therapy
  • Inability for blood withdrawal at baseline
  • Inability or refusal to provide written informed consent.

研究者

相似试验

Cancer-associated venous thromboembolism: unfolding... | 临床试验